Abnormality in prostacyclin-stimulatory activity in sera from diabetics

T. Inoguchi, F. Umeda, H. Ono, M. Kunisaki, J. Watanabe, H. Nawata

    Research output: Contribution to journalArticle

    28 Citations (Scopus)

    Abstract

    A reduction in prostacyclin (PGI2) production by vascular wall may cause platelet hyperaggregability in diabetics, which is considered to be a possible pathogenesis of diabetic vascular complications. In the present study, the presence of PGI2-stimulatory activity (PSA) in rat and human plasma-derived serum (PDS) was confirmed by cultured bovine aortic endothelial cells. PSA in PDS was significantly decreased in streptozotocin-induced diabetic rats and in patients with non-insulin-dependent diabetes mellitus (NIDDM). PDS from patients with NIDDM showed less PSA prior to the clinical onset of diabetic vascular complications, such as retinopathy and proteinuria. The reduction in PSA was still observed in dialyzed PDS from the patients with NIDDM. The nondialyzable PSA was heat-stable at 56°C for 30 minutes and partially stable at 100°C for five minutes. This activity was not extractable with diethylether and was precipitable with tricloroacetic acid. The study of Sephadex G-50 column chromatography showed that a major part of PSA in dialyzed PDS was found in the area of the molecular weight of 12,000 to 17,000 daltons. In conclusion, the reduction in PSA from diabetics may cause a reduction of PGI2 production by vascular wall, subsequently contributing to the development of diabetic vascular complications.

    Original languageEnglish
    Pages (from-to)837-842
    Number of pages6
    JournalMetabolism
    Volume38
    Issue number9
    DOIs
    Publication statusPublished - Sep 1989

      Fingerprint

    All Science Journal Classification (ASJC) codes

    • Endocrinology, Diabetes and Metabolism
    • Endocrinology

    Cite this

    Inoguchi, T., Umeda, F., Ono, H., Kunisaki, M., Watanabe, J., & Nawata, H. (1989). Abnormality in prostacyclin-stimulatory activity in sera from diabetics. Metabolism, 38(9), 837-842. https://doi.org/10.1016/0026-0495(89)90229-1